KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Co-Diagnostics (CODX) Consolidated Net Income (2017 - 2025)

Historic Consolidated Net Income for Co-Diagnostics (CODX) over the last 9 years, with Q3 2025 value amounting to -$5.9 million.

  • Co-Diagnostics' Consolidated Net Income rose 3928.89% to -$5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$32.2 million, marking a year-over-year increase of 2204.92%. This contributed to the annual value of -$37.6 million for FY2024, which is 652.69% down from last year.
  • As of Q3 2025, Co-Diagnostics' Consolidated Net Income stood at -$5.9 million, which was up 3928.89% from -$7.7 million recorded in Q2 2025.
  • In the past 5 years, Co-Diagnostics' Consolidated Net Income registered a high of $11.7 million during Q1 2022, and its lowest value of -$21.9 million during Q4 2022.
  • For the 5-year period, Co-Diagnostics' Consolidated Net Income averaged around -$3.8 million, with its median value being -$6.0 million (2023).
  • In the last 5 years, Co-Diagnostics' Consolidated Net Income soared by 84155.34% in 2021 and then tumbled by 39213.5% in 2022.
  • Co-Diagnostics' Consolidated Net Income (Quarter) stood at $7.5 million in 2021, then crashed by 392.13% to -$21.9 million in 2022, then skyrocketed by 33.0% to -$14.7 million in 2023, then increased by 24.84% to -$11.0 million in 2024, then soared by 46.63% to -$5.9 million in 2025.
  • Its Consolidated Net Income stands at -$5.9 million for Q3 2025, versus -$7.7 million for Q2 2025 and -$7.5 million for Q1 2025.